Puma Biotechnology, Inc. , a development stage biopharmaceutical company, announced that the underwriters for its public offering of 979,592 shares of its common stock at $122.50 per share have elected to exercise in full their option to purchase up to an additional 146,938 shares of common stock at the public offering price, less the underwriting discount.
Business For Sale in Los Angeles News Snippet brought to you by: BizLocal.com
BizLocal provides a Business For Sale Market Place and more.
Sell your business, list your business for sale, find businesses for sale or work with a broker.
BizLocal.com is a web-property of Inspetta LLC, providing innovative web, software and marketing services to business.
Call 800-785-2925 for more information.